Updated from 2:12 p.m. EDT
Positive study data and announcements made at the annual Digestive Disease Week conference edged health stocks slightly higher Tuesday.
said new results from a large cohort study on Prostastcint, which images the extent and spread of prostate cancer, are promising in predicting prognosis of the disease. Shares of the biopharmaceutical company were up 10 cents, or 4.8%, to $2.20.
was up 97 cents, or 1.5%, to $65.97, after the biopharmaceutical company said results from a Phase II study on CC-10004, an oral anti-inflammatory agent, achieved its primary endpoint. The company said it plans to advance the development of its oral anti-inflammatory candidates across a broad range of inflammatory diseases.
announced data that show improvements in symptoms of decreased libido, energy levels and erectile function in 76% of men with diminished testosterone production after they switched to its Testim from
AndroGel. The company's shares rose 99 cents, or 6.5%, to $16.23.
Other industry names used Digestive Disease Week in Washington, D.C., as a platform to present positive study data.
said that long-term data from a follow-up of a Phase I and Phase I/II study suggested that Nuvion, a treatment it is developing for intravenous steroid-refractory ulcerative colitis, an inflammatory bowel disease that attacks the colon, produced a sustained clinical response of up to 310 days and was adequately tolerated. It is also presenting early data regarding the antibody's potential to treat Crohn's disease. The pharmaceutical company's shares were up 54 cents, or 2%, to $27.04.
also announced that Lialda is well tolerated in patients with mild to moderate ulcerative colitis. The company said post-hoc analysis shows that nearly one out of 10 patients taking the once-daily treatment remained relapse-free at the end of a phase III, 12-month extension study. Shire's shares rose 27 cents, or 0.4%, to $69.99.
Though it also offered positive news,
was down 94 cents, or 1.6%, to $57.69. The company said Tuesday that post-hoc analysis of a pivotal study showed patients with moderate to severely active Crohn's disease that received the company's Humira maintenance therapy were nearly 60% less likely than patients on the placebo to be hospitalized because of the disease after a year.
The Amex Biotechnology Index, which includes Celgene and PDL Pharma, was up 5.12, or 0.6%, to 818.28.